SciQuest gives customers full control over chemical inventory with latest ERM upgrade
Used by eight out of the top 10 global pharmaceutical companies, ERM’s newest version includes the industry’s first triple federated search engine.
SciQuest, a leading provider of spend management solutions delivering value beyond savings, has released the latest version of Enterprise Reagent Manager (ERM), the only chemical inventory management software that gives researchers and scientists full and efficient control over research inventory from sourcing and purchase through tracking and disposal.
Used by eight out of the top 10 global pharmaceutical companies, ERM’s newest version includes the industry’s first triple federated search engine, complete with real-time material availability check from suppliers, which allows search across all internal and external sources simultaneously. Through this robust capability, users can now search chemicals by supplier, chemical structure or text description to better meet their research needs.
With near instant startup, ERM 9 is up to 90 percent faster than previous versions. The dynamic and responsive user interface contains one-click tiles for quick navigation to important tasks and status icons that remain with use and display user actions, like items adding to a shopping cart or requesting a container for use from inventory. With the most modern UI that SciQuest has ever developed, ERM is adapted for the tablets and workstations most widely used in today’s research environments.
In addition to the federated search, the ERM 9 upgrade includes the following features:
Held Cart: Allows administrators to control purchases of high cost and/or hazardous materials from non-authorized personnel
“Since ERM closely integrates with procurement, pharmaceutical manufacturers can control complex inventories with reduced general spend and disposal costs, optimized inventory use, and increased regulatory compliance while managing the risks associated with hazardous materials,” said Stephen Wiehe, president and CEO of SciQuest. “With the first and only triple federated search, ERM is so powerful that it even allows the user to start taking action or look up specific information on displayed results, while continuing to receive results for more applicable chemicals or building block compounds.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance